Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
September 16, 2024 07:00 ET
|
Passage Bio
Interim safety and biomarker data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 of PBFT02 achieved robust levels of CSF progranulin in all treated Cohort 1 patients; elevated CSF...
Passage Bio Welcomes Tom Kassberg to Board of Directors
September 10, 2024 07:52 ET
|
Passage Bio
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
August 08, 2024 07:00 ET
|
Passage Bio
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on...
Passage Bio to Participate in Upcoming Investor Conferences
August 06, 2024 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
August 01, 2024 07:00 ET
|
Passage Bio
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA...
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
July 16, 2024 07:00 ET
|
Passage Bio
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan...
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 07:30 ET
|
Passage Bio
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
May 21, 2024 08:00 ET
|
Passage Bio
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
May 14, 2024 07:00 ET
|
Passage Bio
Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with longest...